Here are the 10-K annual reports from Monopar Therapeutics Inc. (MNPR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MNPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNPR filings page.
Monopar Therapeutics filed Amendment No. 1 to its 2025 annual report to correct the date on the independent auditor’s report from March 27, 2025 to March 27, 2026 and update related officer certifications. The amendment re-presents full 2025 financials, which show a net loss of $13.7 million and year-end cash, cash equivalents and investments totaling about $140.7 million against stockholders’ equity of $137.8 million. Management notes an accumulated deficit of $89.5 million and expects existing cash resources to fund operations at least through December 31, 2027.
Monopar Therapeutics Inc. is a clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceuticals for advanced cancers. ALXN1840, in-licensed from Alexion in 2024, has Phase 3 data and U.S./EU orphan and FDA Fast Track designations, but regulators may still require more studies before any approval.
The company is running Phase 1 imaging and therapeutic trials in Australia for MNPR-101-Zr and MNPR-101-Lu, plus an FDA-authorized expanded access program in the U.S., and is advancing MNPR-101-Ac preclinically. Cash, cash equivalents and investments were $140.4 million as of December 31, 2025, which management expects to fund operations at least through December 31, 2027, including an anticipated mid-2026 NDA submission for ALXN1840. The 10-K highlights significant future funding needs to commercialize ALXN1840, complete radiopharmaceutical trials, meet up to $94.0 million in Alexion milestones plus 10–20% tiered royalties, and manage intense competition, manufacturing, logistics, and regulatory risks.